Company: MGLD
Filing Date: 2025-03-07
Form Type: 424B5
Source: 0001493152-25-009595
Chunk: 11

Company: Marygold Companies, Inc.
Filing Date: 2025-03-07
Form: 424B5
Chunk 11
---
 sales agent in any applicable placement notice, and the demand for our common stock during the sales period. Because the price per share of each share sold will fluctuate during the sales period, it is not currently possible to predict the number of shares that will be sold or the gross proceeds to be raised in connection with those sales.

The common stock offered hereby will be sold in “at the market offerings” and investors who buy shares at different times will likely pay different prices.

Investors who purchase shares in this offering at different times may pay different prices, and so they may experience different levels of dilution and different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold in this offering. In addition, there is no minimum or maximum sales price for shares to be sold in this offering. Investors may experience a decline in the value of the shares they purchase in this offering as a result of sales made at prices lower than the prices they paid.

| S-10 |

If you purchase shares of our common stock in this offering, you will incur immediate dilution in the book value of your shares.

The offering price per share of our common stock is expected to be substantially higher than the pro forma net tangible book value per share of our common stock outstanding before this offering. Based upon a public offering price of $1.01 per share (the closing sale price of our common stock on March 5, 2025), you will experience immediate dilution of $0.46 per share with respect to pro forma net tangible book value per share as of December 31, 2024 (adjusted to give effect to the sale of 2,050,000 shares in our recent underwritten public offering and the receipt of the proceeds therefrom). Further, the future exercise of any outstanding options to purchase shares of our common stock or the conversion of outstanding shares of our Series B Preferred Stock will cause you to experience additional dilution. See “Dilution.”

Future issuances or sales, or the potential for future issuances or sales, of our common stock may cause the trading price of our securities to decline and could impair our ability to raise capital through subsequent equity offerings.

We reserve the right to make future offers and sales, either public or private, of our securities including shares of common stock or preferred stock, or securities convertible into, or exercisable for, our common stock at prices differing from the offering price per share of our common stock offered hereby. There can be